Improved survival with ipilimumab in patients with metastatic melanoma.

Hodi, F Stephen et al.·The New England journal of medicine·2010·
RPEP-016272010RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Improved survival with ipilimumab in patients with metastatic melanoma.
Published In:
The New England journal of medicine, 363(8), 711-23 (2010)
Database ID:
RPEP-01627

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-01627·https://rethinkpeptides.com/research/RPEP-01627

APA

Hodi, F Stephen; O'Day, Steven J; McDermott, David F; Weber, Robert W; Sosman, Jeffrey A; Haanen, John B; Gonzalez, Rene; Robert, Caroline; Schadendorf, Dirk; Hassel, Jessica C; Akerley, Wallace; van den Eertwegh, Alfons J M; Lutzky, Jose; Lorigan, Paul; Vaubel, Julia M; Linette, Gerald P; Hogg, David; Ottensmeier, Christian H; Lebbé, Celeste; Peschel, Christian; Quirt, Ian; Clark, Joseph I; Wolchok, Jedd D; Weber, Jeffrey S; Tian, Jason; Yellin, Michael J; Nichol, Geoffrey M; Hoos, Axel; Urba, Walter J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma.. The New England journal of medicine, 363(8), 711-23. https://doi.org/10.1056/NEJMoa1003466

MLA

Hodi, F Stephen, et al. "Improved survival with ipilimumab in patients with metastatic melanoma.." The New England journal of medicine, 2010. https://doi.org/10.1056/NEJMoa1003466

RethinkPeptides

RethinkPeptides Research Database. "Improved survival with ipilimumab in patients with metastati..." RPEP-01627. Retrieved from https://rethinkpeptides.com/research/hodi-2010-improved-survival-with-ipilimumab

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.